
Novel High-Throughput Glycoanalytics for Biopharmaceuticals
Wednesday, July 14, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
Register Free:
Event Overview:
More than two-thirds of biotherapeutics are glycosylated proteins, which includes the therapeutically important category of monoclonal antibodies. The development and manufacturing of these potentially life-changing treatments, however, carries a high risk of failure and is technically challenging and expensive. Glycosylation is a critical product quality attribute that impacts on the efficacy and safety of glycosylated biotherapeutics and, therefore, must be characterized and monitored throughout product development and manufacturing processes.
Key Learning Objectives:
- Review a simplified, rapid, high-throughput and cost-effective platform for characterization and monitoring of the glycosylation profile throughout development and manufacturing
- Learn about a novel approach for safety and potency assurance in biopharmaceuticals
- Use of Octet® platform for high-throughput detection of glycans in biopharmaceutical samples
Who Should Attend:
- Scientists, senior scientists, lab managers, lab directors, or principal scientists working in analytical development, cell line development, process development, bioprocessing, biologics manufacturing, biopharmaceutical quality control, biophysical characterization, protein characterization, titre/titer, potency, stability, or lot release
Speakers
Victoria Smith PhD
Principal Scientist
CPI Biologics
Lewis Wharram
Analytical Scientist
CPI Biologics
Register Free:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.